Faron Pharmaceuticals Oy (LON:FARN) Shares Down 15.2%

Faron Pharmaceuticals Oy (LON:FARN) shares traded down 15.2% on Thursday . The stock traded as low as GBX 192 ($2.44) and last traded at GBX 201.88 ($2.57). 138,103 shares were traded during trading, an increase of 418% from the average session volume of 26,667 shares. The stock had previously closed at GBX 238 ($3.02).

Faron Pharmaceuticals Oy Stock Performance

The company has a debt-to-equity ratio of 121.51, a current ratio of 0.59 and a quick ratio of 1.09. The company’s 50-day moving average price is GBX 154.64 and its two-hundred day moving average price is GBX 222.80. The company has a market capitalization of £141.14 million, a price-to-earnings ratio of -466.20 and a beta of -0.13.

Faron Pharmaceuticals Oy Company Profile

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation.